BridgeBio Pharma (BBIO) Change in Account Payables (2018 - 2026)

BridgeBio Pharma has reported Change in Account Payables for 9 years, with the latest figure at -$7.2 million in Q1 2026.

• Quarterly Change in Account Payables fell 140.81% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 92.53% YoY) and the FY2025 annual result came in at $26.6 million, up 1659.85% from the prior year.
• Change in Account Payables slipped to -$7.2 million in Q1 2026 per BBIO's latest filing, from $17.5 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $17.6 million in Q1 2025 and troughed at -$7.4 million in Q3 2025.
• A 5-year average of $1.4 million and a median of -$1.1 million in 2025 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 5061.41% in 2024, down 618.88% in 2024.
• Over 5 years, Change in Account Payables stood at $1.4 million in 2022, then surged by 349.42% to $6.2 million in 2023, then tumbled by 160.56% to -$3.7 million in 2024, then surged by 567.96% to $17.5 million in 2025, then sank by 140.91% to -$7.2 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$7.2 million, $17.5 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.